Boston University Alzheimer's Disease Research Center

波士顿大学阿尔茨海默病研究中心

• 批准号: 10652548
• 负责人: Ann C. McKee
• 金额: $ 322.91万
• 依托单位: BOSTON UNIVERSITY MEDICAL CAMPUS
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10652548
• 关键词: Acceleration; Address; Advocacy; Affect; Alzheimer' s Disease; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Amyloid; Biological; Biological Markers; Biometry; Blood; Blood Vessels; Books; Boston; Brain Concussion; Cerebral Amyloid Angiopathy; Clinic; Clinical; Clinical Data; Cognitive; Collaborations; Communities; Consultations; Data; Data Collection; Data Set; Deposition; Development; Early identification; Electroencephalography; Ensure; Environmental Risk Factor; Exposure to; Foundations; Framingham Heart Study; Funding; Future; General Population; Genetic; Goals; Grant; Growth; Heart; Heterogeneity; Impaired cognition; Individual; Infrastructure; Late Effects; Lewy Body Disease; Liquid substance; Longevity; Magnetic Resonance Imaging; Mission; Modeling; Molecular Profiling; Nature; Participant; Pathologic; Pathology; Phenotype; Positioning Attribute; Positron-Emission Tomography; Prevention; Privatization; Qualifying; Recommendation; Research; Research Personnel; Research Support; Resources; Risk; Risk Factors; Sampling; Scientist; Secure; Source; Specimen; Spinal Puncture; Strategic vision; Tauopathies; Training; United States National Institutes of Health; Universities; Vascular Diseases; Women' s Health; abeta deposition; age related; analytical tool; biomarker discovery; black women; career development; catalyst; chronic traumatic encephalopathy; cohort; community engagement; contact sports; data management; digital; digital health; education research; experience; follow-up; genetic profiling; head impact; health assessment; high risk; human subject; innovation; interest; military service; molecular phenotype; motor neuron degeneration; neuroimaging; neuroinflammation; neuropathology; next generation; outreach; outreach program; prevent; programs; protein TDP-43; public-private partnership; recruit; research clinical testing; research study; statistics; symposium; tau Proteins; white matter

The Boston University Alzheimer's Disease Research Center (BU ADRC) is committed to the goals and strategies of NAPA including: to prevent and effectively treat AD and AD related dementias (ADRD) by 2025 by expanding AD/ADRD research; to accelerate efforts to identify early and pre-symptomatic stages of AD/ADRD; and to educate the public about AD/ADRD. BU ADRC research themes are congruent with NIH AD/ADRD Research Summit recommendations including: 1) research on heterogeneity and the multifactorial nature of AD/ADRD; 2) molecular profiling of existing and new cohorts; and 3) developing new public-private partnerships. We operationalize our mission through 7 tightly integrated cores: Administrative, Clinical (CC), Data Management and Statistics (DMS), Biomarker, Neuropathology (NPC), Outreach/Recruitment, Engagement (ORE), Genetics and Molecular Profiling (GMP) and a research education component (REC). The Cores are focused on cutting edge research, proactive community engagement, training the next generation of AD/ADRD clinicians and researchers, and sharing key material, data, and expertise both among key partners and with the community at large. The BU ADRC has made significant contributions to the remarkable growth of AD/ADRD research nationally and has actively contributed participants, biological samples, clinical data, and scientific expertise to all major national AD/ADRD research initiatives. The BU ADRC has been the catalyst for exciting new research on genetic and lifespan environmental risk factors and AD/ADRD, particularly vascular risk and exposure to repetitive head impacts (RHI) from contact sports, military service and other sources. Major BU ADRC research themes include studies on RHI from contact sports and military service and risk for AD/ADRD, including chronic traumatic encephalopathy (CTE) and deep phenotyping AD/ADRD heterogeneity with a range of complementary innovative approaches including digital and EEG phenotyping; neuropathology; genetics; biostatistical modelling; biomarker discovery; and molecular profiling. The BU ADRC will build on this strong record of accomplishment to support new research and educate the next generation of AD/ADRD scientists. The BU ADRC will also support high risk high gain innovative developmental projects focused on NAPA and NIA strategic goals and utilize our collective expertise and experience to facilitate career development of investigators with diverse backgrounds. The BU ADRC will develop new partnerships and enhance current partnerships with other ADRCs and national research programs, foundations, advocacy groups and private organizations in our quest to prevent and treat AD/ADRD. Exposure to RHI is associated with CTE and a wide range of other AD/ADRD pathologies. As recognized leaders in this space, we are uniquely positioned to support research on genetic and other risks factors and study how RHI affects the clinical course, biomarker profile, and clinical-pathological features of AD/ADRD including CTE.

波士顿大学阿尔茨海默氏病研究中心（BU ADRC）致力于目标和 NAPA的策略包括：预防和有效治疗AD和AD相关痴呆症（ADRD），到2025年 扩大广告/ADRD研究；加速努力以确定AD/ADRD的早期和症状阶段； 并向公众教育广告/adrd。 BU ADRC研究主题与NIH AD/ADRD一致 研究峰会建议包括：1）关于异质性和多因素性质的研究 广告/adrd; 2）现有和新队列的分子分析； 3）发展新的公私 伙伴关系。我们通过7个紧密整合的核心来实现我们的任务：行政，临床（CC）， 数据管理和统计（DMS），生物标志物，神经病理学（NPC），外展/招聘， 参与（矿石），遗传学和分子分析（GMP）和研究教育部分（REC）。 核心专注于尖端研究，积极的社区参与，训练下一个 生成广告/ADRD临床医生和研究人员，并共享关键材料，数据和专业知识 关键合作伙伴以及整个社区。 BU ADRC为 广告/ADRD在全国范围内的显着增长，并积极贡献参与者，生物学 所有主要国家广告/ADRD研究计划的样本，临床数据和科学专业知识。 bu ADRC一直是关于遗传和寿命环境危险因素的令人兴奋的新研究的催化剂 广告/ADRD，特别是血管风险和接触运动，军事体育的重复性头部影响（RHI） 服务和其他来源。主要的BU ADRC研究主题包括有关接触体育和RHI的研究 兵役和AD/ADRD的风险，包括慢性创伤性脑病（CTE）和Deep 表型广告/ADRD异质性具有一系列互补的创新方法，包括数字 和脑电表型；神经病理学；遗传学；生物统计建模；生物标志物发现；和分子 分析。 BU ADRC将基于这一有力的成就记录，以支持新的研究和 教育下一代广告/ADRD科学家。 BU ADRC还将支持高风险高收益 创新的发展项目侧重于NAPA和NIA战略目标，并利用我们的集体专业知识 和经验，以促进具有不同背景的调查员的职业发展。 BU ADRC将 建立新的合作伙伴关系并加强与其他ADRC和国家研究的当前合作伙伴关系 计划，基金会，倡导团体和私人组织，以预防和治疗广告/ADRD。 接触RHI与CTE和其他广泛的AD/ADRD病理有关。如认可 在这个领域的领导者，我们在支持遗传和其他风险因素以及 研究RHI如何影响AD/ADRD的临床过程，生物标志物谱和临床病理特征 包括CTE。

项目成果

Visualizing reactive astrocyte-neuron interaction in Alzheimer's disease using 11C-acetate and 18F-FDG.

• DOI: 10.1093/brain/awad037
• 发表时间: 2023-04
• 期刊: Brain : a journal of neurology
• 作者: Min-Ho Nam;H. Ko;Dongwoo Kim;Sangwon Lee;Yongmin Mason Park;Seung Jae Hyeon;Woojin Won;Jee-in Chung;Seon yoo Kim;Hanhee Jo;Kyeongtaek Oh;Young-eun Han;G. Lee;Y. Ju;Hyowon Lee;Hyunjin Kim;Jaejun Heo;Mridula Bhalla;Ki Jung Kim;Jea Kwon;T. Stein;Mingyu Kong;Hyunbeom Lee;Seung Eun Lee;Soo-Jin Oh;Joong-Hyun Chun;Mi-Ae Park;Ki Duk Park;Hoon Ryu;M. Yun;C. J. Lee

Accelerated Breakdown of Phosphatidylcholine and Phosphatidylethanolamine Is a Predominant Brain Metabolic Defect in Alzheimer's Disease.

• DOI: 10.3233/jad-230061
• 发表时间: 2023-05
• 期刊: Journal of Alzheimer's disease : JAD
• 作者: J. Blusztajn;B. Slack

Amyloid PET ordering practices in a memory disorders clinic.

• DOI: 10.1002/trc2.12333
• 发表时间: 2022
• 期刊: ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS
• 影响因子: 4.8
• 作者: Turk, Katherine W;Vives-Rodriguez, Ana;Schiloski, Kylie A;Marin, Anna;Wang, Ryan;Singh, Prabhjyot;Hajos, Gabor P;Powsner, Rachel;DeCaro, Renee;Budson, Andrew E
• 通讯作者: Budson, Andrew E

Three dimensional evaluation of cerebrovascular density and branching in chronic traumatic encephalopathy.

• DOI: 10.1186/s40478-023-01612-y
• 发表时间: 2023-07-25
• 期刊: Acta neuropathologica communications
• 影响因子: 7.1

Educating students while recruiting underrepresented populations for Alzheimer's disease research: the Student Ambassador Program.

• DOI: 10.1186/s12909-022-03749-1
• 发表时间: 2022-10-05
• 期刊: BMC MEDICAL EDUCATION
• 影响因子: 3.6
• 作者: DeCaro, Renee;O'Connor, Maureen K.;DiTerlizzi, Christina;Sekyi-Appiah, Nana;Polk, John;Budson, Andrew E.
• 通讯作者: Budson, Andrew E.